Precision Biosciences Inc
DTIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.53M
Close$
$16.72
94.6% upside
Current Fair Value
94.6% upsideUndervalued by 94.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $113.53 Million |
|---|---|
| Enterprise Value | $29.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.56 |
| Beta | 1.23 |
| Outstanding Shares | 25,856,628 |
Return
| Return on Equity | -116.42% |
|---|---|
| Return on Assets | -41.88% |
| Return on Invested Capital | -38.08% |
Valuation & Multiples
| P/E Ratio | -3.17 |
|---|---|
| PEG | -8.17 |
| Price to Sales | 8.59 |
| Price to Book Ratio | 8.59 |
| Enterprise Value to Revenue | 0.65 |
| Enterprise Value to EBIT | -0.64 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$740,000
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$1.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 20,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 65.56%▼ 52.14% |
|---|---|
| Total Invested | $88.11M▲ 40.32% |
| Investors Holding | 78▲ 11.00% |
ESG Score
No data
About Precision Biosciences Inc
CEO: Matthew Kane